A. J. SABNIS ET AL: "FGFR Fusions in the Driver's Seat", CANCER DISCOVERY, vol. 3, no. 6, 1 June 2013 (2013-06-01), pages 607-609, XP055206314, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-13-0185 (B1)

Y.-M. WU ET AL: "Identification of Targetable FGFR Gene Fusions in Diverse Cancers", CANCER DISCOVERY, vol. 3, no. 6, 4 April 2013 (2013-04-04), pages 636-647, XP055123926, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-13-0050 (B1)

D. SINGH ET AL: "Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma", SCIENCE, vol. 337, no. 6099, 26 July 2012 (2012-07-26), pages 1231-1235, XP055237736, US ISSN: 0036-8075, DOI: 10.1126/science.1220834 (B1)

DATABASE Geneseq [Online] 27 November 2008 (2008-11-27), "Human FGFR 2 mRNA target sequence for mdRNA, SEQ ID:3954.", XP055257043, retrieved from EBI accession no. GSN:ATM46802 Database accession no. ATM46802 (B1)

DATABASE Geneseq [Online] 7 November 2013 (2013-11-07), "FGFR3-TACC3 gene fusion PCR primer, FGFR3-TACC3(F18T11)_qPCR_F SEQ:15.", XP002753027, retrieved from EBI accession no. GSN:BAT14432 Database accession no. BAT14432 (B1)

EP-A1- 1 659 175 (B1)

EP-A1- 1 964 837 (B1)

Makito Miyake ET AL: "1- tert -Butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-di ethylamino-butylamino)-pyrido[2,3- d ]pyrimidin-7-yl]-urea (PD173074), a Selective Tyrosine Kinase Inhibitor of Fibroblast Growth Factor Receptor-3 (FGFR3), Inhibits Cell Proliferation of Bladder Cancer Carrying the FGFR3 Gene Mutation along with Up-", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 332, no. 3, 2 December 2009 (2009-12-02), pages 795-802, XP055626351, US ISSN: 0022-3565, DOI: 10.1124/jpet.109.162768 (B1)

QING JING ET AL: "Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice", JOURNAL OF CLINICAL INVESTIGATION, B M J GROUP, GB, vol. 119, no. 5, 1 May 2009 (2009-05-01), pages 1216-1229, XP002594035, ISSN: 0021-9738, DOI: 10.1172/JCI38017 [retrieved on 2009-04-20] (B1)

S. V. WILLIAMS ET AL: "Oncogenic FGFR3 gene fusions in bladder cancer", HUMAN MOLECULAR GENETICS, vol. 22, no. 4, 15 February 2013 (2013-02-15), pages 795-803, XP055105338, ISSN: 0964-6906, DOI: 10.1093/hmg/dds486 (B1)

SHINMURA KAZUYA ET AL: "A novel somatic FGFR3 mutation in primary lung cancer", ONCOLOGY REPORTS, SPANDIDOS PUBLICATIONS, GR, vol. 31, no. 3, 1 March 2014 (2014-03-01), pages 1219-1224, XP008170551, ISSN: 1791-2431, DOI: 10.3892/OR.2014.2984 [retrieved on 2014-01-20] (B1)

TRUDEL SUZANNE ET AL: "Evaluation of XL999, a potent inhibitor of FGFR3, for the potential treatment of t(4;14) positive multiple myeloma", BLOOD, vol. 110, no. 11, Part 1, November 2007 (2007-11), pages 741A-742A, XP055241142, & 49TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 08 -11, 2007 ISSN: 0006-4971 (B1)

US-A1- 2013 296 326 (B1)

WO-A1-2013/087725 (B1)

WO-A1-2013/179034 (B1)

WO-A1-2014/007369 (B1)

WO-A1-2014/018841 (B1)

WO-A1-2014/051022 (B1)

WO-A2-2013/089882 (B1)

WO-A2-2014/071419 (B1)

WO-A2-2014/113729 (B1)

BRITTANY C. PARKER ET AL: "The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma", JOURNAL OF CLINICAL INVESTIGATION, vol. 123, no. 2, 1 February 2013 (2013-02-01), pages 855-865, XP055127845, ISSN: 0021-9738, DOI: 10.1172/JCI67144 & Brittany C Parker ET AL: "Supplementary data for The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma", Journal of Clinical Investigation, vol. 123, no. 2, 1 February 2013 (2013-02-01), pages 855-865, XP055127920, ISSN: 0021-9738 (B1)